TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02007798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 100 ml per bag
Study: NCT02967367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyMedia Sense Wear accelerometer
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
Study: NCT03993938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI measurement
Description: Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
Study: NCT01399593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study: NCT01563068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: Topical application applied twice a day for 15 days
Study: NCT00009919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV
Study: NCT02378766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website A
Description: Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change.

Intervention type: OTHER
Group type: OTHER
Intervention: Website B
Description: Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
Study: NCT02437565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stainless steel crown
Description: Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal Template
Description: Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
Study: NCT01393769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
Study: NCT04689126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical or nonsurgical endodontic treatment
Description: Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
Study: NCT02598791

Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
Study: NCT04317248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Signals loaded Dendritic Cells Vaccine
Description: one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Signals loaded Dendritic Cells Vaccine
Description: one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Signals loaded Dendritic Cells Vaccine
Description: one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
Study: NCT05149417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminding
Description: patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: telemonitoring
Description: Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemonitoring
Description: Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
Study: NCT02099214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3Tesla cardiac MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3Tesla cardiac MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (EKG)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iron and cardiac markers
Description: Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Beta-hCG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Transthoracic echocardiograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Transthoracic echocardiograph

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urinary pregnancy test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3Tesla abdominal MRI
Study: NCT02499393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: intravenous infusion of magnesium sulphate
Study: NCT02311751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study: NCT01955070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Presentation for Ketamine sedation
Description: PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Presentation for Ketamine sedation
Description: PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
Study: NCT02598791

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GIP
Description: Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
Study: NCT03595878

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Parotid sparing WBRT
Description: Whole Brain Radiation Therapy with avoidance of the parotid glands

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard WBRT
Description: Standard Whole Brain Radiation Therapy
Study: NCT03869593

Intervention type: GENETIC
Intervention: Sample analysis
Description: Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
Study: NCT00557791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Description: Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Description: Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Description: Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
Study: NCT04349722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide
Description: Intervention is given once a participant is in established labor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention is given once a participant is in established labor
Study: NCT02598791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GLP-1
Description: glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+NaCl (placebo)
Description: i.v. NaCl during isoglycemia

Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: 50 g oral glucose tolerance test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Description: 50 g oral glucose tolerance test

Intervention type: OTHER
Group type: OTHER
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Study: NCT01563263

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: 100 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline (PBS) solution containing 0,9 % NaCl
Study: NCT00575965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Oral tablets taken daily
Study: NCT03712683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
Study: NCT02598791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IIGI+GIP+GLP-1
Description: i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Study: NCT04034329

Intervention type: PROCEDURE
Intervention: ASVAL
Description: Ambulatory Selective Varices Ablation under Local Anesthesia

Intervention type: PROCEDURE
Intervention: EVLA
Description: Endovenous Laser Ablation
Study: NCT01469416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg PO x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg PO x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
Study: NCT02113904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 6 injections (one every 15 days during 3 months)
Study: NCT02783976

Intervention type: DRUG
Intervention: Sovaldi
Description: Sovaldi 400 mg tablets administered orally once daily
Study: NCT00879255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy Group In-Person
Description: Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
Study: NCT03885843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal nerve stimulation, mapping and denervation
Description: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure: Renal angiography
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
Study: NCT01043692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
Study: NCT02654054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study: NCT02618161

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR Brachytherapy
Description: HDR Brachytherapy, a single dose of 15 Gy delivered to prostate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy
Description: HDR Brachytherapy, a single dose of 15 Gy delivered to prostate

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam Radiotherapy
Description: External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam Radiotherapy
Description: External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
Study: NCT02301949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study: NCT04327947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Research product 1
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 1
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 1
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Research product 2
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 2
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Research product 2
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid - Comparator product
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Comparator product
Description: Health care product (intimate gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid - Comparator product
Description: Health care product (intimate gel)
Study: NCT01416948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride 20 mg
Description: For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine 12 mg
Description: For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
Study: NCT04142294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Histidine
Description: ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Histidine
Description: ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Histidine
Description: ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Histidine
Description: ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
Study: NCT00649428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblast (azficel-T)
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face.